IGM Biosciences (IGM Biosciences) 3-Year FCF Growth Rate : -12.10% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences 3-Year FCF Growth Rate?

IGM Biosciences's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.75.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -12.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of IGM Biosciences was 58.10% per year. The lowest was -24.10% per year. And the median was -12.85% per year.

Competitive Comparison of IGM Biosciences's 3-Year FCF Growth Rate

For the Biotechnology subindustry, IGM Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGM Biosciences's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's 3-Year FCF Growth Rate falls into.

IGM Biosciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

IGM Biosciences (NAS:IGMS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

IGM Biosciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences (IGM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

1K0:Germany

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Executives

Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Fred Schwarzer	director, officer: CEO and President	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt	officer: Chief Scientific Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Lisa Lynn Decker	officer: Chief Business Officer	C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
George Gauthier	officer: Chief Commercial Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chris H Takimoto	officer: Chief Medical Officer	C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Misbah Tahir	officer: Chief Financial Officer	325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z.	director	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Christina Teng Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Jakob Haldor Topsoe	director, 10 percent owner	325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Steven Weber	officer: Principal Accounting Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014